Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1, D-Trp5,7,9,Leu11]SP: A dual inhibitor of growth and angiogenesis in pancreatic cancer

Cancer Research

Volumn 65, Issue 7, 2005, Pages 2738-2745

  Guha, Sushovan ^a,b   Eibl, Guido ^b,c   Kisfalvi, Krisztina ^a,b   Fan, Robert S ^a,b   Burdick, Marie ^a   Reber, Howard ^c   Hines, Oscar J ^c   Strieter, Robert ^a,b   Rozengurt, Enrique ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ION; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CXCL 8; CHEMOKINE RECEPTOR CXCR2; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR ANTAGONIST; INTERLEUKIN 8; KI 67 ANTIGEN; PROTEIN INHIBITOR; SUBSTANCE P DERIVATIVE; SUBSTANCE P[1 DEXTRO ARGININE 5,7,9 DEXTRO TRYPTOPHAN 11 LEUCINE]; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALCIUM MOBILIZATION; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CORNEA; DNA SYNTHESIS; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; MALE; MITOGENESIS; MOUSE; NONHUMAN; NUDE MOUSE; PANCREAS CANCER; PANCREAS DUCT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; RAT; STATISTICAL SIGNIFICANCE; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; CARCINOMA, PANCREATIC DUCTAL; CELL GROWTH PROCESSES; CORNEA; DNA, NEOPLASM; HUMANS; INTERLEUKIN-8; KI-67 ANTIGEN; MALE; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; PANCREATIC NEOPLASMS; RATS; RECEPTORS, G-PROTEIN-COUPLED; SUBSTANCE P; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 16844365620     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-3197     Document Type: Article

References (32)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004:54;8-29.
2. Brand RE, Tempero MA. Pancreatic cancer. Current Opinion in Oncology 1998:10;362-6.
3. Rozengurt E. Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. Curr Opin in Oncol 1999:11;116-22.
4. Rozengurt E. Neuropeptides as growth factors for normal and cancer cells. Trends Endocrinol Metab 2002:13;128-34.
5. Ryder NM, Guha S, Hines OJ, Reber HA, Rozengurt E. G protein-coupled receptor signaling in human ductal pancreatic cancer cells: neurotensin responsiveness and mitogenic stimulation. J Cell Physiol 2001:186;53-64.
6. Guha S, Lunn JA, Santiskulvong C, Rozengurt E. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1. Cancer Res 2003:63;2379-87.
7. Guha S, Rey O, Rozengurt E. Neurotensin induces protein kinase C-dependent protein kinase D activation and DNA synthesis in human pancreatic carcinoma cell line PANC-1. Cancer Res 2002:62;1632-40.
8. Kisfalvi K, Guha S, Rozengurt E. Neurotensin and EGF induce synergistic stimulation of DNA synthesis by increasing the duration of ERK signaling in ductal pancreatic cancer cells. J Cell Physiol 2005:202;880-90.
9. Strieter RM, Belperio JA, Phillips RJ, Keane MP. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 2004:14;195-200.
10. Shi Q, Abbruzzese JL, Huang S, Fidler IJ, Xiong Q, Xie K. Constitutive and inducible interleukin 8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res 1999:5;3711-21.
11. Langdon S, Sethi T, Ritchie A, Muir M, Smyth J, Rozengurt E. Broad spectrum neuropeptide antagonists inhibit the growth of small cell lung cancer in vivo. Cancer Res 1992:52;4554-7.
12. Woll PJ, Rozengurt E. A neuropeptide antagonist that inhibits the growth of small cell lung cancer in vitro. Cancer Res 1990:50;3968-73.
13. Clive S, Webb DJ, MacLellan A, et al. Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. Clin Cancer Res 2001:7;3071-8.
14. 11]substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res 1997:57;51-4.
15. Raut CP, Takamori RK, Davis DW, Sweeney-Gotsch B, O'Reilly MS, McConkey DJ. Direct effects of recombinant human endostatin on tumor cell IL-8 production are associated with increased endothelial cell apoptosis in an orthotopic model of human pancreatic cancer. Cancer Biol Ther 2004:3;7.
16. Scott IS, Morris LS, Bird K, et al. A novel immunohistochemical method to estimate cell-cycle phase distribution in archival tissue: implications for the prediction of outcome in colorectal cancer. J Pathol 2003:201;187-97.
17. Keane MP, Belperio JA, Xue YY, Burdick MD, Strieter RM. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004:172;2853-60.
18. Rhee SH, Keates AC, Moyer MP, Pothoulakis C. MEK is a key modulator for TLR5-induced interleukin-8 and MIP3α gene expression in non-transformed human colonic epithelial cells. J Biol Chem 2004:279;25179-88. Epub 2004 Apr; 25176.
19. Lane BR, Liu J, Bock PJ, et al. Interleukin-8 and growth-regulated oncogene alpha mediate angiogenesis in Kaposi's sarcoma. J Virol 2002:76;11570-83.
20. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ. Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 1995:376;517-9.
21. Bennett MW, O'Connell J, O'Sullivan GC, et al. Fas ligand and Fas receptor are coexpressed in normal human esophageal epithelium: a potential mechanism of apoptotic epithelial turnover. Dis Esophagus 1999:12;90-8.
22. Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res 2004:64;622-30.
23. Ebert M, Yokoyama M, Friess H, Kobrin MS, Buchler MW, Korc M. Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer. Int J Cancer 1995:62;529-35.
24. Eibl G, Bruemmer D, Okada Y, et al. PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun 2003:306;887-97.
25. Hotz HG, Reber HA, Hotz B, et al. An orthotopic nude mouse model for evaluating pathophysiology and therapy of pancreatic cancer. Pancreas 2003:26;e89-98.
26. Murphy LO, Abdel-Wahab YH, Wang OJ, et al. Receptors and ligands for autocrine growth pathways are up-regulated when pancreatic cancer cells are adapted to serum-free culture. Pancreas 2001:22;293-8.
27. Klein WM, Hruban RH, Klein-Szanto AJ, Wilentz RE. Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol 2002:15;441-7.
28. Eibl G, Reber HA, Wente MN, Hines OJ. The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas 2003:26;33-41.
29. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995:1;149-53.
30. 11]Substance P acts as a biased agonist toward neuropeptide and chemokine receptors. J Biol Chem 1998:273;3097-104.
31. Sinnett-Smith J, Santiskulvong C, Duque J, Rozengurt E. [D-Arg(1),D-Trp(5,7,9),Leu(11)]Substance P inhibits bombesin-induced mitogenic signal transduction mediated by both G(q) and G(12) in Swiss 3T3cells. J Biol Chem 2000:275;30644-52.
32. 8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism. Methods Mol Med 2003:74;299-307.